Cargando...

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

PURPOSE: Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negative breast cancer (TNBC). We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Nanda, Rita, Chow, Laura Q.M., Dees, E. Claire, Berger, Raanan, Gupta, Shilpa, Geva, Ravit, Pusztai, Lajos, Pathiraja, Kumudu, Aktan, Gursel, Cheng, Jonathan D., Karantza, Vassiliki, Buisseret, Laurence
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2016
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6816000/
https://ncbi.nlm.nih.gov/pubmed/27138582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.8931
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!